Tolterodine
- Generic Name
- Tolterodine
- Brand Names
- Detrol, Detrusitol
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO
- CAS Number
- 124937-51-5
- Unique Ingredient Identifier
- WHE7A56U7K
- Background
Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors.
- Indication
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence).
- Associated Conditions
- Urinary Urge Incontinence
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 260
- Registration Number
- NCT01604928
- Locations
- 🇧🇪
Site: 12, Brussels, Belgium
🇧🇪Site: 13, Edegem, Belgium
🇧🇪Site: 11, Gent, Belgium
The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms
- Conditions
- Disorder of Urinary Stent
- Interventions
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- Urmia University of Medical Sciences
- Target Recruit Count
- 104
- Registration Number
- NCT01530243
- Locations
- 🇮🇷
Imam Khomeini Hospital, Urmia, Azerbaijan-gharbi, Iran, Islamic Republic of
Pharmacokinetics and Relative Bioavailability Study
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01521767
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2012-01-19
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Lee's Pharmaceutical Limited
- Target Recruit Count
- 324
- Registration Number
- NCT01512004
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Beijing, China
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
- Conditions
- Overactive BladderOveractive Urinary Bladder
- Interventions
- Other: Placebo (vibegron)Other: Placebo (tolterodine ER)Drug: Prophylactic Antibiotic
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 4
- Registration Number
- NCT01500382
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 11157
- Registration Number
- NCT01488578
Study of Herbmed Plus in Ureteral Stent Discomfort
- Conditions
- Ureteral Stent Discomfort
- Interventions
- First Posted Date
- 2011-05-19
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Dr .S.B.PATANKAR
- Target Recruit Count
- 140
- Registration Number
- NCT01356355
- Locations
- 🇮🇳
AMAI Charitable Trust's ACE Hospital Pune, Pune, Maharashtra, India
A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2011-03-15
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1395
- Registration Number
- NCT01314872
Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01302938
- Locations
- 🇺🇸
Mytrus, Inc., San Francisco, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
GABAergic Modulation in Pain Transmission in Human: Effect of the GABAA Agonist Clobazam on Peripheral and Central Sensitisation
- Conditions
- Neuropathic Pain
- Interventions
- First Posted Date
- 2011-02-08
- Last Posted Date
- 2011-12-14
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 25
- Registration Number
- NCT01291316
- Locations
- 🇨🇭
University Hospitals, Geneva, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.